

# **MRSD: a novel quantitative approach for assessing the suitability of RNA-seq in the clinical investigation of mis-splicing in Mendelian disease**

## **Supplementary Material**

### **Supplementary Table 1**

Summary of pathogenic splicing variants analyzed during this study 3

### **Supplementary Table 2**

Summary of datasets used in this study 4

### **Supplementary Figure 1**

Categories of potentially pathogenic splicing events and their representation in analytical pipeline output 5

### **Supplementary Figure 2**

Sequencing depths of RNA-seq samples used for evaluation of MRSD model accuracy 6

### **Supplementary Figure 3**

Effect of varying sequencing read length on MRSD model performance 7

### **Supplementary Figure 4**

Evidence for 3' sequencing bias confounding the use of TPM as a guiding RNA-seq metric 8

### **Supplementary Figure 5**

Exemplar events identified during pathogenic splice event analysis 9

### **Supplementary Figure 6**

Relative gene expression level does not reflect the raw read coverage of transcript splice junctions 10

### **Supplementary Figure 7**

Pairwise comparisons, by tissue, of MRSD scores for PanelApp disease genes 11

### **Supplementary Figure 8**

Proportion of low-MRSD genes per tissue for all PanelApp panels, ordered by panel size

- a) Low-MRSD gene proportions for large panels (> 50 genes) 12
- b) Low-MRSD gene proportions for medium panels (21-50 genes) 13
- c) Low-MRSD gene proportions for small panels (11-20 genes) 14
- d) Low-MRSD gene proportions for very small panels ( $\leq$  10 genes) 15

**Supplementary Figure 9**

Proportion of low-MRSD genes per tissue for all PanelApp panels, ordered alphabetically by panel name

<b>a) Low-MRSD gene proportions for panels named A-E</b>	16
<b>b) Low-MRSD gene proportions for panels named F-L</b>	17
<b>c) Low-MRSD gene proportions for panels named M-X</b>	18

**Supplementary Figure 10**

The potential power of RNA-seq for resolving ClinVar variants of uncertain significance (VUSs)

19

**Supplementary Methods 1**

Illustration of MRSD calculation methodology

20

**Supplementary Methods 2**

Tiering methodology for selection of transcripts for MRSD generation

21

**Supplementary Methods 3**

Tissue-specific criteria for filtering of high-quality GTEx control RNA-seq datasets

22

**Supplementary Methods 4**

Sample IDs of GTEx samples used to generate control datasets

<b>Skeletal muscle</b>	23
<b>Whole blood</b>	25
<b>EBV-transformed lymphocytes (LCLs)</b>	27
<b>Cultured fibroblasts</b>	28

**References**


30

Variant (HGVSg)	Gene	Source of RNA	Phenotype	TPM	MRSD (M reads)
chr2:152,355,017G>T					
chr2:152,389,953A>C	NEB		Nemaline myopathy	857.9	9.83
chr2:152,544,805C>T					
chrX:31,790,694-31,798,498invdel	DMD		Duchenne muscular dystrophy		
chrX:32,274,692G>A		Skeletal muscle	Myalgia, myoglobinuria	24.84	79.4
chr2:179,642,185G>A	TTN		Multi/minicore congenital myopathy	349.5	47.63
chr21:47,409,881C>T	COL6A1		Collagen VI-related dystrophy	56.02	16.25
chr21:47,409,881C>T					
chr19:38,958,362C>T	RYR1		Congenital fiber-type disproportion	425.5	3.45
chr1:46,655,129C>A	POMGNT1		$\alpha$ -Dystroglycanopathy	29.26	6.01
chr17:41,199,655C>G					
chr17:41,246,879T>C	BRCA1				
chr17:41,246,879T>C		LCL	Inherited breast cancer susceptibility	19.985	217.19
chr17:41,258,551C>A					
chr13:32,945,238G>A	BRCA2			10.16	Unfeasible
chr13:32,969,074A>T					
chr19:33,892,776C>T	PEPD		Prolidase deficiency	18.89	28.31
chr20:35,526,363C>G	SAMHD1	Whole blood	Aicardi-Goutières syndrome	48.53	24.68
chr23:153,997,595G>A	DKC1		Dyskeratosis congenita	102.01	8.59


**Supplementary Table 1.** Summary of pathogenic splicing events analyzed in this study. All co-ordinates are given in relation to the GRCh37 genome build. TPM, transcripts per million; MRSD, minimum required sequencing depth.

Tissue	No. samples	Source	Sequencing type	Usage
Blood	151	GTEx	75-bp paired end poly-A enrichment, Illumina	Generation of MRSD model, bootstrapping analysis of event counts
LCL	91			
Muscle	184			
Blood	1	Inhouse	150-bp paired end globin depletion, Illumina	Collation of known pathogenic mis-splicing events
	12		75-bp paired end poly-A enrichment, Illumina	Collation of known pathogenic mis-splicing events & MRSD model validation
LCL	20	Inhouse	150-bp paired end poly-A enrichment, Illumina	Collation of known pathogenic mis-splicing events
	4		75-bp paired end poly-A enrichment, Illumina	MRSD model validation
Muscle	52	Previously published data [1]	75-bp paired end poly-A enrichment, Illumina	Collation of known pathogenic mis-splicing events, downsampling of pathogenic events & MRSD model validation


**Supplementary Table 2.** Summary of RNA-seq datasets utilized in this study. RNA-seq datasets derived using different methodologies were used for various aspects of this study. All data used to generate the MRSD model was based on data from the GTEx consortium across all three analyzed tissues.




**Supplementary Figure 1.** *Categories of potentially pathogenic splicing events and their representation in analytical pipeline output.* Disruption of (a) wild-type splicing may lead to (b) skipping of one or more exons, the creation of novel splice sites in (c) exonic or (d) intronic regions that may outcompete the canonical sites, or result in (e) the generation of an intronic pseudoexon. (f) Splicing may be abrogated completely, leading to total retention of the intron. (g) Within longer exons, creation of a novel splice site may lead to a so-called “exitron”, whereby a central portion of the exon is absent from the final transcript. Green triangles indicate canonical splice sites; red triangles indicate non-canonical sites.




**Supplementary Figure 2.** Sequencing depths of RNA-seq samples used for evaluation of MRSD model accuracy. Whole blood ( $n = 12$ ), LCL ( $n = 4$ ) and skeletal muscle ( $n = 52$ ) RNA-seq samples were derived from in-house or previously published data [1] for validation of the MRSD model efficacy. Sequencing depths across the three tissues ranged from 20.6-281.5 M uniquely mapping reads.




**Supplementary Figure 3. Effect of varying sequencing read length on MRSD model performance.** Despite being derived from 75 bp paired end RNA-seq data, MRSD scores show similar performance when applied to 75 or 150 bp paired end read-based RNA-seq, both in terms of (top) PPV and (bottom) NPV. When specifying 75% splice junction coverage, MRSD PPV is generally higher when the model is applied to 150 bp read-based data. This likely reflects the fact that junctions predicted to be sufficiently covered by 75 bp reads will be more likely to be sufficiently covered by reads of greater length, and so positive predictions are more likely to hold true when applied to longer-read data. We also observe that NPV for 150 bp read datasets is lower than that for 75 bp across all 4 parameter combinations; conversely to PPV, this is possibly because transcripts not sufficiently covered by 75 bp reads are more likely to be sufficiently covered by 150 bp reads, thus making negative predictions less likely to hold true in longer-read data. In most cases, differences in model performance between 75 and 150 bp is low, suggesting MRSD may, in some cases, provide a suitable approximation of transcript coverage in RNA-seq datasets with read lengths different to those used to construct the model.



**Supplementary Figure 4. Evidence for 3' sequence bias confounding the use of TPM as a guiding RNA-seq metric.** Analysing the number of reads (per 1 M uniquely mapping input reads) mapping to individual splice junctions within three genes with substantial TPM-MRSD discrepancy demonstrates that highly expressed genes may exhibit biased coverage of splice junctions. For IGHM (top) and ALDOA (middle) in LCLs and muscle, respectively, a sufficient proportion of junctions towards the 3' end of the transcript have no read support in a sufficient number of patients, resulting in an MRSD prediction of "unfeasible", despite high coverage of other junctions within the same transcript. Coverage of the final two splice junctions in RPL10 (bottom) in LCL-based RNA-seq data is low but not non-zero in many patients, giving a feasible but high MRSD prediction. In some cases, this bias may result from artefacts of library preparation, or may possibly reflect genuine isoform shifts in the given tissue. Higher splice junction numbers represent junctions closer to the 3' end of transcripts.




**Supplementary Figure 5.** Exemplar events identified during pathogenic splice event analysis. Selected Sashimi plots for (a) exon skipping, (b) exonic splice gain, (c) pseudoexonization and (d) intron retention events identified as the cause of disease in our patient datasets. The presence of aberrant splice junctions with outlying event metrics allowed flagging of these as potentially pathogenic. For (d), the intron retention event was identified from the 2 reads supporting usage of an extremely weak alternative splice acceptor four bases downstream of the abrogated canonical acceptor; however, in the absence of any aberrant splicing events, intron retention events are more difficult to identify from RNA-seq data using current bioinformatics pipelines.




**Supplementary Figure 6.** *Relative gene expression level does not reflect the raw read coverage of transcript splice junctions.* When simulating decreased gene expression by downsampling reads in genes containing novel splicing events identified in upstream analysis, it emerged that expression of a gene (in transcripts per million, TPM) does not directly correlate with the number of reads supporting splice junctions in that gene. Among the events supported by 8 reads, for example, gene expression ranged from 0.17-52 TPM. This may be accounted for by variation in the proportion of transcripts containing the event, variation in the coverage across the length of a transcript (as shown in Supplementary Figure 4), or variation in the depth to which a sample has been sequenced. Thus, when specifying a metric threshold above which we expect splice aberration to be observable, relative expression level may not appropriately represent expected read support. Axes are limited for ease of visualization.

**Supplementary Figure 7.** Pairwise comparisons, by tissue, of predicted MRSD scores for PanelApp disease genes.

**a) MRSD predictions in muscle vs. blood**




**b) MRSD predictions in LCLs vs. muscle**




**Supplementary Figure 8.** Proportion of low-MRSD genes per tissue for all PanelApp panels, ordered by panel size.

**a) Low-MRSD gene proportions for large panels (> 50 genes)**



## b) Low-MRSD gene proportions for medium panels (21-50 genes)



### c) Low-MRSD proportions for small panels (11-20 genes)



#### d) Low-MRSD gene proportions for very small panels ( $\leq 10$ genes)



**Supplementary Figure 9.** Proportion of low-MRSD genes per tissue for all PanelApp panels, ordered alphabetically by panel name.

**a) Low-MRSD gene proportions for panels named A-E**




## b) Low-MRSD proportions for panels named F-L



### c) Low-MRSD gene proportions for panels named M-X






**Supplementary Figure 10.** The potential power of RNA-seq for resolving ClinVar variants of uncertain significance (VUSs). Similarly to Figure 7 (main text), we analyzed the distribution of MRSD predictions for genes harbouring ClinVar VUSs with SpliceAI predictions  $> 0.25$  [2]. Of the 185,119 ClinVar variants annotated as “Uncertain significance” or “Conflicting interpretations of pathogenicity”, 13,602 (7.3%) passed this threshold, and so were deemed “predicted splice-impacting”. **(a)** Across all parameter combinations, a greater number of variants were in genes that were predicted low-MRSD (MRSD  $\leq 100$  M reads) in LCLs than in any other tissue. Dependent on parameter stringency, between 22.3% and 59.2% of variants were in genes predicted low-MRSD in at least one of the three tissues. **(b)** Among the 30 genes containing the largest number of predicted splice-impacting VUSs in ClinVar, 22 were predicted low-MRSD in at least one of the three tissues.

**Supplementary Methods 1. Illustration of MRSD calculation methodology.** MRSD scores utilize the level of read coverage supporting the existence of splice junctions in control RNA-seq datasets to predict the depth of sequencing required to achieve a specified level of splice junction coverage. In a given individual and gene:


1. Read coverage values are collated across all splice junctions in the transcript model for that gene (see Supplementary Methods 2, below)
2. Each of these values is divided by the sequencing depth – by default defined as the number of uniquely mapping sequencing reads – and multiplied by  $10^6$  to produce a per-1 M read coverage value for each junction
3. The desired level of read coverage is divided by the per-1 M read coverage value of the splice junction with the  $X^{\text{th}}$  percentile lowest read coverage, which gives the depth of sequencing that would be required for  $X\%$  of junctions to be covered with the desired number of reads or higher. This figure is the sample-specific MRSD.

This process is iterated across all control RNA-seq samples to generate a list of sample-specific MRSDs, and a global MRSD is then derived by taking the  $Z^{\text{th}}$  percentile highest prediction from among these ( $Z$  corresponding to the so-called *confidence level*, i.e. the proportion of control RNA-seq samples for which that level of sequencing would have sufficiently covered that gene).

#### 1. Collation of splice junction read supports




#### 2. Calculation of per-1 M read coverage




#### 3. Inference of MRSD for specified coverage parameters

e.g. for 75% of splice junctions to be covered by 8 reads or more:



**Supplementary Methods 2. Tiering methodology for selection of transcripts for MRSD generation.** To calculate MRSD values for all protein-coding genes, a single transcript model was established for each gene. Firstly, transcripts present in the MANE v0.7 curated transcript set were selected for genes where these existed, provided the co-ordinates of all splice junctions in that transcript (given in relation to the GRCh38 reference genome) mapped back to known junctions in build GRCh37. For genes where these conditions were not met, transcript models were formed from the union of all junctions present in all RefSeq transcripts listed for that gene on Ensembl BioMart. Finally, for any genes lacking a corresponding RefSeq transcript, a transcript model was derived consisting of the union of all junctions present in all transcripts assigned to that gene in the GENCODE v19 annotation.



**Supplementary Methods 3.** *Tissue-specific criteria for filtering of high-quality GTEx control RNA-seq datasets.* Filtering of GTEx controls was conducted to select the highest quality samples based on the below tissue-specific parameters. Parameters were selected and adjusted on a tissue-by-tissue basis to exclude metric outliers and samples that may confound analysis of pathogenic splicing events (e.g. excluding cancer patients from LCL control cohorts, in which inherited breast cancer was studied). The corresponding column names in the GTEx v8 sample attribute (pht002743.v8) and subject phenotype (pht002742.v8) files are italicized.

*Skeletal muscle (as listed in [1])*

- RNA integrity number/RIN (*SMRIN*): between 6-9
- Sample ischemic time (*SMTSISCH*): <720 (i.e. <12 hours)
- Hardy scale (*DTHHRDY*): 0, 1 or 2, corresponding to sudden deaths
- Age (*AGE*): <50
  - Unless BMI <30

*Whole blood*

- Samples included in GTEx analysis freeze, corresponding to higher quality samples (*SMAFRZE*): not flagged EXCLUDE due to technical issues
- RIN (*SMRIN*): between 6-9
- Sample ischemic time (*SMTSISCH*): <0
- Hardy scale (*DTHHRDY*): 0, 1 or 2

*EBV-transformed lymphocytes (LCLs)*

- *SMAFRZE*: not flagged EXCLUDE due to technical issues
- RIN (*SMRIN*): > 9
- *MHCANCER5*, *MHCANCERC* and *MHCANCERNM* all 0 to eliminate all non-metastatic cancers and all cancers in the past 5 years or current
- *DTHHRDY*: 0, 1 or 2
- No reported history (*MHGENCMT*) of:
  - Breast cancer
  - Ovarian cancer
  - Pancreatic cancer
  - Prostate cancer
  - Colorectal cancer
  - No patients filtered out through this criterion

*Cultured fibroblasts*

- As for EBV-transformed lymphocytes, except with the addition of the following:
  - RIN (*SMRIN*) > 9.7
  - Uniquely mapping reads (*MPPDUN*): > 60 M

**Supplementary Methods 4.** Sample IDs of GTEx samples used to generate control datasets.

**Skeletal muscle** (as listed in [1])

GTEX-111CU-2026	GTEX-OIZH-1626
GTEX-111YS-2326	GTEX-OOBJ-1626
GTEX-1122O-2426	GTEX-P4PP-1626
GTEX-113JC-2726	GTEX-P4PQ-1626
GTEX-117YX-2526	GTEX-P78B-1626
GTEX-11DXX-2726	GTEX-POMQ-1926-SM-3NB1Y
GTEX-11DXZ-2426	GTEX-POYW-0526-SM-2XCEY
GTEX-11EM3-2126	GTEX-PSDG-0426
GTEX-11EMC-2626	GTEX-PWCY-2026
GTEX-11EQ9-2126	GTEX-Q2AH-1826-SM-2S1Q2
GTEX-11I78-2426	GTEX-Q734-2026-SM-3GADA
GTEX-11LCK-1226	GTEX-QCQG-2126-SM-2S1P8
GTEX-11NSD-2026	GTEX-QDVN-2426-SM-2S1Q4
GTEX-11P81-2526	GTEX-QV44-2026-SM-2S1RD
GTEX-11P82-1826	GTEX-R53T-1826-SM-3GIJX
GTEX-11VI4-1926	GTEX-R55D-0626-SM-3GAD5
GTEX-11WQC-2626	GTEX-S32W-2326-SM-2XCAW
GTEX-11WQK-0726	GTEX-S33H-2226
GTEX-11XUK-2226	GTEX-S7SF-2026-SM-3K2AS
GTEX-11ZTT-2626	GTEX-SNMC-1426-SM-2XCFM
GTEX-11ZVC-2726	GTEX-SUCS-1626-SM-32PLS
GTEX-1211K-2126	GTEX-T5JC-0626-SM-3NMA6
GTEX-12BJ1-2526	GTEX-T5JW-1826-SM-3GAE1
GTEX-12C56-1926	GTEX-TKQ2-0826-SM-33HB6
GTEX-12WSJ-1726	GTEX-TML8-1826-SM-32QOR
GTEX-12WSN-2526	GTEX-TMMY-0426-SM-33HBB
GTEX-12ZZX-0326	GTEX-U3ZG-0326-SM-47JXN
GTEX-12ZZY-0626	GTEX-U3ZH-1926-SM-4DXTR
GTEX-13111-2226	GTEX-U3ZM-1226-SM-3DB9G
GTEX-1314G-1726	GTEX-U4B1-1626-SM-3DB8N
GTEX-131XF-2326	GTEX-UJHI-1726-SM-3DB9B
GTEX-131XG-2326	GTEX-UJMC-1826-SM-3GADT
GTEX-132AR-1026	GTEX-VUSG-2626-SM-4KKZI
GTEX-132NY-0726	GTEX-WHPG-2226-SM-3NMBO
GTEX-1339X-2426	GTEX-WHSB-1826-SM-3TW8M
GTEX-133LE-2026	GTEX-WOFM-1326-SM-3MJFR
GTEX-1399Q-2426	GTEX-WRHK-1626-SM-3MJFH
GTEX-1399R-2526	GTEX-WRHU-0826-SM-3MJFN
GTEX-1399S-2726	GTEX-WXYG-2526-SM-3NB3F
GTEX-1399U-2526	GTEX-WY7C-2526-SM-3NB2N
GTEX-139D8-0726	GTEX-WZTO-0826-SM-3NM8Q
GTEX-139UW-2626	GTEX-X4XY-0626-SM-4E3IN
GTEX-139YR-2526	GTEX-X638-0326-SM-47JY1
GTEX-13CF3-1826	GTEX-X88G-0326-SM-47JZ4
GTEX-13D11-2526	GTEX-XBEC-0626
GTEX-13FH7-2126	GTEX-XBED-2626-SM-4E3J5
GTEX-13FHO-0726	GTEX-XBEW-1026
GTEX-13FTW-2326	GTEX-XOTO-0526-SM-4B662
GTEX-13FTY-0226	GTEX-XPT6-2026-SM-4B64V

GTEX-13FXS-0326	GTEX-XQ8I-0626-SM-4BOPT
GTEX-13JUV-2326	GTEX-XUJ4-2626-SM-4BOQ3
GTEX-13N11-2726	GTEX-XUW1-0826-SM-4BOP6
GTEX-13N2G-2326	GTEX-XUYS-0326-SM-47JX2
GTEX-13NZ9-0626	GTEX-XUZC-2126-SM-4BRW8
GTEX-13NZB-2626	GTEX-XV7Q-2926-SM-4BRUL
GTEX-13O61-2326	GTEX-XYKS-2426-SM-4AT43
GTEX-13OVG-2126	GTEX-Y114-2526
GTEX-13OVH-0626	GTEX-Y3IK-2626
GTEX-13OVI-1726	GTEX-Y5LM-2126
GTEX-13OW6-0626	GTEX-Y5V5-2526
GTEX-13PL7-0626	GTEX-Y5V6-2626
GTEX-13PVR-2526	GTEX-Y8E4-1026
GTEX-13QBU-2426	GTEX-Y8E5-0326
GTEX-13QJ3-0726	GTEX-Y8LW-2026
GTEX-13S7M-0326	GTEX-Y9LG-1926
GTEX-13S86-2326	GTEX-YB5E-2226
GTEX-13U4I-1826	GTEX-YB5K-2326
GTEX-13VXT-0326	GTEX-YBZK-0326
GTEX-13W3W-2626	GTEX-YEC3-2126
GTEX-13W46-0726	GTEX-YEC4-2226
GTEX-13YAN-0526	GTEX-YF7O-2526
GTEX-144GL-0326	GTEX-YFC4-1026
GTEX-144GM-2026	GTEX-Z9EW-1726
GTEX-144GN-2426	GTEX-ZA64-2026
GTEX-145LT-1626	GTEX-ZAKK-0326
GTEX-145LV-2326	GTEX-ZC5H-0326
GTEX-145ME-2026	GTEX-ZDYS-1726
GTEX-145MI-0326	GTEX-ZPCL-2026
GTEX-145MN-2426	GTEX-ZPIC-2526
GTEX-146FH-0526	GTEX-ZQG8-1226
GTEX-146FQ-0326	GTEX-ZQUD-1726
GTEX-147F3-0226	GTEX-ZT9X-1826
GTEX-1497J-2626	GTEX-ZTPG-0126
GTEX-14A6H-2826	GTEX-ZTX8-1626
GTEX-14AS3-2126	GTEX-ZV6S-2126
GTEX-14BMV-0326	GTEX-ZV7C-2426
GTEX-14C39-2426	GTEX-ZVZO-0326
GTEX-14ICL-1926	GTEX-ZVZP-2526
GTEX-O5YT-1626-SM-32PK6	GTEX-ZY6K-2026
GTEX-OHPK-1626-SM-2YUN3	GTEX-ZYFG-2426
GTEX-OHPL-1626	GTEX-ZYWO-2626
GTEX-OHPM-1626	GTEX-ZZ64-1526

## Whole blood

GTEX-113JC-0006-SM-5O997  
GTEX-1192W-0005-SM-5NQBQ  
GTEX-11DXX-0005-SM-5NQ8B  
GTEX-11EMC-0006-SM-5O9DN  
GTEX-11GSP-0006-SM-5N9EL  
GTEX-11I78-0005-SM-5N9GB  
GTEX-11LCK-0005-SM-5O98U  
GTEX-11OF3-0006-SM-5O9CM  
GTEX-11ONC-0005-SM-5O9CY  
GTEX-11P7K-0006-SM-5N9FM  
GTEX-11P82-0006-SM-5N9FY  
GTEX-11TT1-0005-SM-5NQ8Y  
GTEX-11VI4-0006-SM-5N9D8  
GTEX-11WQK-0005-SM-5O9AV  
GTEX-11ZTT-0006-SM-5N9FX  
GTEX-1212Z-0006-SM-5NQ8M  
GTEX-1269C-0005-SM-5N9CJ  
GTEX-12C56-0006-SM-5N9E9  
GTEX-12KS4-0005-SM-5SI94  
GTEX-12WSI-0005-SM-5O99K  
GTEX-12WSK-0006-SM-5NQA1  
GTEX-12WSM-0005-SM-5NQB3  
GTEX-12WSN-0006-SM-5NQAP  
GTEX-12ZZX-0005-SM-5O9A9  
GTEX-13113-0006-SM-5NQ7X  
GTEX-1314G-0005-SM-5NQ9O  
GTEX-131XE-0006-SM-5P9F9  
GTEX-131XG-0006-SM-5O9CE  
GTEX-132NY-0005-SM-5O9AC  
GTEX-1399R-0006-SM-5N9FR  
GTEX-139UW-0005-SM-5NQ8U  
GTEX-13CF3-0006-SM-5N9ED  
GTEX-13FTX-0005-SM-5N9F6  
GTEX-13FXS-0006-SM-5O99X  
GTEX-13OVG-0005-SM-5P9HA  
GTEX-13OVH-0005-SM-5P9HB  
GTEX-13OVI-0001-SM-5O9BL  
GTEX-13OVK-0006-SM-5O9B7  
GTEX-13OVL-0006-SM-5O996  
GTEX-13OW6-0005-SM-5NQ9Z  
GTEX-13OW8-0005-SM-5NQAC  
GTEX-13PL7-0005-SM-5N9ET  
GTEX-13S7M-0005-SM-5NQ76  
GTEX-13VXT-0005-SM-5N9F3  
GTEX-147F3-0005-SM-5N9FI  
GTEX-147JS-0006-SM-5NQ7K  
GTEX-148VI-0006-SM-5O9A6  
GTEX-14A5H-0006-SM-5O9AI  
GTEX-14AS3-0006-SM-5NQC2  
GTEX-14B4R-0006-SM-5O9A7  
GTEX-14BMV-0005-SM-5NQ6Y  
GTEX-14C38-0006-SM-5NQBF  
GTEX-14C39-0005-SM-5NQBR  
GTEX-QEG5-0006-SM-2I5FZ  
GTEX-QESD-0006-SM-2I5G6  
GTEX-R55C-0005-SM-3GAE9  
GTEX-RWS6-0005-SM-2XCAN  
GTEX-S341-0006-SM-3NM8D  
GTEX-SSA3-0005-SM-32QOT  
GTEX-T5JW-0005-SM-3GADE  
GTEX-T6MN-0005-SM-32PLJ  
GTEX-T6MO-0006-SM-32QOU  
GTEX-T8EM-0006-SM-3DB71  
GTEX-TKQ1-0006-SM-33HBI  
GTEX-TKQ2-0006-SM-33HBH  
GTEX-TML8-0005-SM-32QPA  
GTEX-TMZS-0006-SM-3DB8G  
GTEX-U3ZG-0006-SM-47JWX  
GTEX-U3ZH-0005-SM-3DB72  
GTEX-U4B1-0006-SM-3DB8E  
GTEX-UJMC-0005-SM-3GACU  
GTEX-UPJH-0006-SM-3GACW  
GTEX-V1D1-0006-SM-3NMCE  
GTEX-V955-0005-SM-3P5ZC  
GTEX-VJYA-0005-SM-3P5ZD  
GTEX-VUSG-0006-SM-3GIK9  
GTEX-WCDI-0005-SM-3NB2M  
GTEX-WFG7-0005-SM-3GIKM  
GTEX-WFON-0005-SM-3NMC9  
GTEX-WH7G-0005-SM-3NMBX  
GTEX-WHPG-0006-SM-3NMBV  
GTEX-WHSB-0005-SM-3LK7C  
GTEX-WHWD-0005-SM-3LK7D  
GTEX-WOFL-0006-SM-3TW8K  
GTEX-WOFM-0005-SM-3MJF3  
GTEX-WQUQ-0006-SM-3MJF4  
GTEX-WRHK-0005-SM-3MJF5  
GTEX-WRHU-0006-SM-3MJF6  
GTEX-WVLH-0006-SM-3MJF7  
GTEX-WXYG-0005-SM-3NB3M  
GTEX-WY7C-0006-SM-3NB3L  
GTEX-WYVS-0006-SM-3NMA7  
GTEX-WZTO-0006-SM-3NM9T  
GTEX-X15G-0005-SM-3NMDA  
GTEX-X3Y1-0006-SM-3P5ZG  
GTEX-X5EB-0006-SM-46MV5  
GTEX-X638-0005-SM-47JX6  
GTEX-X88G-0006-SM-47JX5  
GTEX-XBED-0006-SM-47JXO  
GTEX-XBEW-0006-SM-4AT4E  
GTEX-XMK1-0005-SM-4B665  
GTEX-XPT6-0006-SM-4B66Q  
GTEX-XXEK-0005-SM-4BRWJ  
GTEX-XYKS-0005-SM-4BRUD  
GTEX-Y114-0006-SM-4TT76  
GTEX-Y5LM-0005-SM-4V6EJ

GTEX-14DAR-0006-SM-5N9GC	GTEX-Y5V5-0006-SM-4V6FE
GTEX-14E1K-0006-SM-5N9DY	GTEX-Y5V6-0005-SM-4V6FD
GTEX-14H4A-0006-SM-5N9E3	GTEX-Y8E4-0006-SM-4V6EW
GTEX-14ICK-0006-SM-5NQB5	GTEX-Y8E5-0006-SM-47JWQ
GTEX-14ICL-0006-SM-5SIAB	GTEX-Y8LW-0005-SM-4V6EV
GTEX-N7MT-0007-SM-3GACQ	GTEX-Y9LG-0006-SM-4VBRK
GTEX-O5YT-0007-SM-32PK7	GTEX-YB5K-0005-SM-4VDSP
GTEX-O5YW-0006-SM-3LK6E	GTEX-YBZK-0005-SM-59HKG
GTEX-OHPL-0006-SM-3MJHB	GTEX-YFC4-0006-SM-4RGLV
GTEX-OIZF-0006-SM-2I5GQ	GTEX-ZC5H-0005-SM-4WAXM
GTEX-OIZI-0005-SM-2XCED	GTEX-ZDYS-0002-SM-4WKGR
GTEX-OXRP-0006-SM-2I3FN	GTEX-ZE9C-0006-SM-4WKG2
GTEX-P4QS-0005-SM-2I3EY	GTEX-ZF29-0006-SM-4WKGQ
GTEX-P78B-0005-SM-2I5GM	GTEX-ZGAY-0006-SM-4WWAQ
GTEX-PLZ5-0006-SM-5S2W5	GTEX-ZP4G-0006-SM-4WWE6
GTEX-PLZ6-0006-SM-33HBZ	GTEX-ZPIC-0005-SM-4WWEB
GTEX-POMQ-0006-SM-5SI7D	GTEX-ZPU1-0006-SM-4WWAT
GTEX-PSDG-0005-SM-3GADC	GTEX-ZQG8-0005-SM-4YCEH
GTEX-PVOW-0006-SM-3NMB8	GTEX-ZQUD-0005-SM-4YCE5
GTEX-PW2O-0006-SM-2I3DV	GTEX-ZVE2-0006-SM-51MRW
GTEX-PWCY-0005-SM-33HBP	GTEX-ZVP2-0005-SM-51MRK
GTEX-Q2AG-0005-SM-5SI7F	GTEX-ZVT2-0005-SM-57WBW
GTEX-Q2AH-0005-SM-33HBR	GTEX-ZVZP-0006-SM-51MSW
GTEX-Q2AI-0006-SM-2I3FG	GTEX-ZXES-0005-SM-57WCB
GTEX-QCQG-0006-SM-5SI8M	

## EBV-transformed lymphocytes (LCLs)

GTEX-1122O-0003-SM-5Q5DL	GTEX-XBED-0003-SM-47JWP
GTEX-11EM3-0001-SM-5Q5BD	GTEX-XBEW-0002-SM-4AT5O
GTEX-11EMC-0002-SM-5Q5DO	GTEX-XGQ4-0004-SM-4AT5S
GTEX-11OC5-0004-SM-5S2O6	GTEX-XMK1-0001-SM-4B64F
GTEX-11P7K-0003-SM-5S2OU	GTEX-XPT6-0001-SM-4B64G
GTEX-11TT1-0004-SM-5S2NT	GTEX-XQ3S-0001-SM-4B64K
GTEX-11VI4-0001-SM-5S2OI	GTEX-XXEK-0004-SM-4BRWO
GTEX-1212Z-0002-SM-5SI6W	GTEX-XYKS-0002-SM-4BRWN
GTEX-1269C-0003-SM-5S2PB	GTEX-Y114-0002-SM-4TT78
GTEX-12BJ1-0003-SM-5SI6V	GTEX-Y3IK-0001-SM-4WWE1
GTEX-12C56-0002-SM-5S2PC	GTEX-Y5LM-0003-SM-4V6G1
GTEX-RWS6-0001-SM-3NMAL	GTEX-Y5V5-0001-SM-4V6FZ
GTEX-S4Q7-0003-SM-3NM8M	GTEX-Y5V6-0003-SM-4V6FX
GTEX-S95S-0002-SM-3NM8K	GTEX-Y8DK-0004-SM-4RGM7
GTEX-SN8G-0001-SM-3NM8L	GTEX-Y8E4-0003-SM-4V6FY
GTEX-T5JC-0001-SM-3NMAK	GTEX-Y9LG-0001-SM-4VBRQ
GTEX-T5JW-0003-SM-3NMAD	GTEX-YB5E-0001-SM-4VDSV
GTEX-T6MN-0002-SM-3NMAH	GTEX-YB5K-0003-SM-4VDSN
GTEX-T6MO-0003-SM-3NMAG	GTEX-YEC3-0002-SM-4W1YI
GTEX-TKQ1-0003-SM-3NMAE	GTEX-YEC4-0002-SM-4W1Z6
GTEX-TML8-0001-SM-3NMAF	GTEX-YF7O-0004-SM-4W1ZT
GTEX-U3ZH-0002-SM-3NMDD	GTEX-YFCO-0003-SM-4W21I
GTEX-U3ZM-0002-SM-3NMMD	GTEX-ZC5H-0004-SM-4WAXK
GTEX-U3ZN-0002-SM-3NMDF	GTEX-ZDTS-0001-SM-4WAXW
GTEX-UPJH-0001-SM-3NMDE	GTEX-ZDTT-0004-SM-4WKG3
GTEX-UPK5-0003-SM-3NMDI	GTEX-ZEX8-0004-SM-4WKFQ
GTEX-V1D1-0003-SM-3NMDP	GTEX-ZF29-0002-SM-4WKF2
GTEX-VJYA-0001-SM-3NMDJ	GTEX-ZF2S-0004-SM-4WKFE
GTEX-VUSG-0003-SM-3NMDK	GTEX-ZF3C-0001-SM-4WWAW
GTEX-W5WG-0002-SM-3NMDN	GTEX-ZG7Y-0003-SM-4WWEJ
GTEX-W5X1-0001-SM-3P61V	GTEX-ZLWG-0004-SM-4WWD5
GTEX-WFG7-0001-SM-3P61S	GTEX-ZP4G-0003-SM-4WWED
GTEX-WFG8-0001-SM-4LVN8	GTEX-ZPIC-0002-SM-4WWEC
GTEX-WFJO-0002-SM-3P61X	GTEX-ZPU1-0004-SM-4WWAV
GTEX-WFON-0001-SM-3P61W	GTEX-ZQG8-0001-SM-4YCDH
GTEX-WHPG-0004-SM-3NMDO	GTEX-ZQUD-0003-SM-4YCD3
GTEX-WHSB-0002-SM-4M1ZR	GTEX-ZT9W-0003-SM-4YCE6
GTEX-WOFM-0001-SM-4OOT2	GTEX-ZT9X-0004-SM-4YCDT
GTEX-WRHK-0001-SM-4WWDD	GTEX-ZTPG-0002-SM-4YCEI
GTEX-WWTW-0002-SM-4MVNH	GTEX-ZUA1-0002-SM-4YCF7
GTEX-WXYG-0004-SM-4MVOS	GTEX-ZV6S-0003-SM-4YCCT
GTEX-WY7C-0004-SM-4OND\$	GTEX-ZV7C-0003-SM-4YCF6
GTEX-WYVS-0004-SM-4OND\$	GTEX-ZVT2-0001-SM-57WCK
GTEX-WZTO-0001-SM-4PQZY	GTEX-ZVTK-0003-SM-51MRV
GTEX-X4LF-0002-SM-4QASG	GTEX-ZVZP-0004-SM-51MS8
GTEX-X5EB-0004-SM-46MWA	

## Cultured fibroblasts

GTEX-111YS-0008-SM-5Q5BH	GTEX-T2IS-0008-SM-4DM75
GTEX-113JC-0008-SM-5QGR6	GTEX-T5JC-0008-SM-4DM6A
GTEX-117XS-0008-SM-5Q5DQ	GTEX-U4B1-0008-SM-4DXUW
GTEX-1192W-0008-SM-5QGRE	GTEX-U8T8-0008-SM-4DXSP
GTEX-11DXX-0008-SM-5Q5B8	GTEX-UJHI-0008-SM-4IHL1
GTEX-11DXY-0008-SM-5QGR4	GTEX-UJMC-0008-SM-4IHKK
GTEX-11EMC-0008-SM-5Q5DR	GTEX-UPK5-0008-SM-4IHJD
GTEX-11GSP-0008-SM-5Q5DM	GTEX-V1D1-0008-SM-4JBIJ
GTEX-11I78-0008-SM-5Q5DI	GTEX-W5X1-0008-SM-4LMKA
GTEX-11LCK-0008-SM-5Q5BB	GTEX-WFG7-0008-SM-4LMKB
GTEX-11NSD-0008-SM-5Q5BC	GTEX-WHPG-0008-SM-4M1ZQ
GTEX-11NUK-0008-SM-5Q5B9	GTEX-WHSB-0008-SM-4M1ZP
GTEX-11NV4-0008-SM-5Q5BA	GTEX-WHWD-0008-SM-4OOSU
GTEX-11O72-0008-SM-5Q5DN	GTEX-WI4N-0008-SM-4OOSV
GTEX-11OC5-0008-SM-5S2OH	GTEX-WL46-0008-SM-4OOSW
GTEX-11OF3-0008-SM-5S2NH	GTEX-WQUQ-0008-SM-4OOT1
GTEX-11ONC-0008-SM-5S2MG	GTEX-WRHU-0008-SM-4MVPB
GTEX-11P7K-0008-SM-5S2O5	GTEX-WVJS-0008-SM-4MVPC
GTEX-11P81-0008-SM-5S2OT	GTEX-WVLH-0008-SM-4MVPD
GTEX-11P82-0008-SM-5S2MS	GTEX-WY7C-0008-SM-4ONDW
GTEX-11PRG-0008-SM-5S2N5	GTEX-WYBS-0008-SM-4ONDX
GTEX-11TT1-0008-SM-5S2P8	GTEX-WYJK-0008-SM-4ONDV
GTEX-11TUW-0008-SM-5SI6S	GTEX-WYVS-0008-SM-4ONDY
GTEX-11WQC-0008-SM-5SI6R	GTEX-WZTO-0008-SM-4PQZZ
GTEX-11WQK-0008-SM-5SI6T	GTEX-X15G-0008-SM-4PR2D
GTEX-11XUK-0008-SM-5S2WD	GTEX-X3Y1-0008-SM-4PR12
GTEX-11ZTS-0008-SM-5S2VC	GTEX-X4LF-0008-SM-4QAST
GTEX-11ZTT-0008-SM-5S2TZ	GTEX-XBEC-0008-SM-4AT3X
GTEX-11ZUS-0008-SM-5S2UO	GTEX-XBEW-0008-SM-4AT3Y
GTEX-1211K-0008-SM-5S2W1	GTEX-XMD2-0008-SM-4WWE7
GTEX-12126-0008-SM-5S2UC	GTEX-XMD3-0008-SM-4AT4V
GTEX-12WSH-0008-SM-5S2V1	GTEX-XMK1-0008-SM-4GICF
GTEX-12WSM-0008-SM-5S2VD	GTEX-XOT4-0008-SM-4B664
GTEX-1399U-0008-SM-5S2VE	GTEX-XPT6-0008-SM-4B64Q
GTEX-N7MS-0008-SM-4E3JI	GTEX-XPVG-0008-SM-4GICH
GTEX-NFK9-0008-SM-4E3JE	GTEX-XQ3S-0008-SM-4GIDZ
GTEX-NL3G-0008-SM-4E3JX	GTEX-XUW1-0008-SM-4BOQH
GTEX-O5YT-0008-SM-4E3IQ	GTEX-XV7Q-0008-SM-4BRWL
GTEX-O5YW-0008-SM-4E3IE	GTEX-Y8E4-0008-SM-4V6FW
GTEX-OHPK-0008-SM-4E3JL	GTEX-Y9LG-0008-SM-4VBRJ
GTEX-OHPL-0008-SM-4E3I9	GTEX-YB5K-0008-SM-4VDT8
GTEX-OHPM-0008-SM-4E3IP	GTEX-YEC4-0008-SM-4W1YR
GTEX-OHPN-0008-SM-4E3HW	GTEX-YF7O-0008-SM-4W1ZS
GTEX-OIZG-0008-SM-4E3J2	GTEX-YJ89-0008-SM-4RGM4
GTEX-OIZI-0008-SM-2XCFD	GTEX-Z93S-0008-SM-4RGM5
GTEX-OOBJ-0008-SM-3NB26	GTEX-ZC5H-0008-SM-4WAX8
GTEX-OOBK-0008-SM-3NB27	GTEX-ZDTS-0008-SM-4E3I8
GTEX-OXRK-0008-SM-3NB28	GTEX-ZDTT-0008-SM-4E3K5

GTEX-OXRL-0008-SM-3NB29	GTEX-ZDXO-0008-SM-4E3HR
GTEX-P4PP-0008-SM-48TDV	GTEX-ZDYS-0008-SM-4E3IX
GTEX-P4QT-0008-SM-48TDZ	GTEX-ZE7O-0008-SM-4E3JQ
GTEX-PSDG-0008-SM-48TE5	GTEX-ZEX8-0008-SM-4E3JU
GTEX-PW2O-0008-SM-48TEB	GTEX-ZF2S-0008-SM-4E3IK
GTEX-PWCY-0008-SM-48TE9	GTEX-ZF3C-0008-SM-4E3IL
GTEX-PX3G-0008-SM-48U2L	GTEX-ZLWG-0008-SM-4E3J4
GTEX-Q2AH-0008-SM-48U2J	GTEX-ZP4G-0008-SM-4E3I4
GTEX-QCQG-0008-SM-48U2G	GTEX-ZPIC-0008-SM-4E3JF
GTEX-QLQ7-0008-SM-447AW	GTEX-ZPU1-0008-SM-4E3IR
GTEX-QXCU-0008-SM-48FCH	GTEX-ZQG8-0008-SM-4E3J9
GTEX-R45C-0008-SM-48FF2	GTEX-ZQUD-0008-SM-4YCCU
GTEX-R55C-0008-SM-48FCF	GTEX-ZT9W-0008-SM-4YCDJ
GTEX-R55D-0008-SM-48FEV	GTEX-ZT9X-0008-SM-4YCD7
GTEX-R55E-0008-SM-48FCG	GTEX-ZTPG-0008-SM-4YCEK
GTEX-R55G-0008-SM-48FEX	GTEX-ZTX8-0008-SM-4YCDV
GTEX-RM2N-0008-SM-48FF3	GTEX-ZUA1-0008-SM-4YCEW
GTEX-RN64-0008-SM-48FEZ	GTEX-ZV68-0008-SM-4YCCV
GTEX-RNOR-0008-SM-48FEY	GTEX-ZV6S-0008-SM-4YCF9
GTEX-RU1J-0008-SM-46MV9	GTEX-ZV7C-0008-SM-57WCL
GTEX-RU72-0008-SM-46MV8	GTEX-ZVE2-0008-SM-51MRU
GTEX-RWS6-0008-SM-47JYV	GTEX-ZVP2-0008-SM-51MSL
GTEX-RWSA-0008-SM-47JYX	GTEX-ZVT2-0008-SM-57WC9
GTEX-S33H-0008-SM-4AD6C	GTEX-ZVT3-0008-SM-51MRI
GTEX-S4Z8-0008-SM-33HAZ	GTEX-ZVTK-0008-SM-57WDA
GTEX-SE5C-0008-SM-4B64J	GTEX-ZVZP-0008-SM-51MSX
GTEX-SJXC-0008-SM-4DM7G	GTEX-ZXES-0008-SM-57WCX

## **References**

1. Cummings BB, Marshall JL, Tukiainen T, Lek M, Donkervoort S, Foley AR, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. *Sci Transl Med.* 2017;9(386).
2. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting Splicing from Primary Sequence with Deep Learning. *Cell.* 2019;176(3):535-48.e24.